Pletaal 50 mg 20 tablets

Tradename

Pletaal

Pletaal

Composition

Each tablet contains:

Cilostazol 50 mg

Auxiliary components:

Starch, microcrystalline cellulose, carmelose calcium, hypromellose and magnesium stearate.

Properties

PDE type 3 inhibitor (PDE3). Increases the content of intracellular cyclic adenosine monophosphate (cAMP) in various organs and tissues.

Cilostazol dilates mainly the femoral arterie to a lesser extent — the vertebral, carotid an superior mesenteric arteries. The renal arteries

are not sensitive to the effects of cilostazol.

Indications

Symptomatic treatment for intermittent claudication.

Cilostazol is used to increase the maximum distance and distance traveled without pain in patients with intermittent claudication who have no pain at rest and no signs of peripheral tissue necrosis (Fontaine’s grade Il chronic lower limb ischemia).

Cilostazol is intended for use as a second-line therapy in patients with intermittent claudication in whom lifestyle changes (including smoking cessation and physical rehabilitation programs) and other appropriate interventions have not been sufficient to reduce symptoms of intermittent claudication.

Contraindications

Hypersensitivity to cilostazol, severe renal failure (CC 05 ml / min); moderate or severe hepatic impairment; chronic heart failure; predisposition to bleeding (for example, peptic ulcer of the stomach or duodenal ulcer in the acute phase, recently (within the last 6 months) suffered a hemorrhagic stroke, proliferative diabetic retinopathy, poorly controlled arterial hypertension); history of ventricular tachycardia, ventricular fibrillation or polytopic ventricular premature beats (regardless of the presence or absence of adequate antiarrhythmic therapy); an extended QT interval on an ECG; history of severe tachyarrhythmia; unstable angina or myocardial infarction within the past 6 months; invasive coronary artery intervention in the past 6 months; taking two or more antiplatelet or anticoagulant drugs at the same time (eg, acetylsalicylic acid, clopidogrel, heparin, warfarin, acenocoumarol, dabigatran, rivaroxaban, or apixaban); concomitant use of potent inhibitors of CYP3A4 or CYP2C19 (for example, cimetidine, diltiazem, erythromycin, ketoconazole, lansoprazole, omeprazole and HIV-I protease inhibitors); pregnancy; breastfeeding period; age under 18. concomitant use of potent inhibitors of

CYP3A4 or CYP2C19 (for example, cimetidine, diltiazem, erythromycin, ketoconazole, lansoprazole, omeprazole and HIV-I protease inhibitors); pregnancy; breastfeeding period; age under 18. concomitant use of potent inhibitors of CYP3A4 or CYP2C19 (for example, cimetidine, diltiazem, erythromycin, ketoconazole, lansoprazole, omeprazole and HIV-I protease inhibitors); pregnancy; breastfeeding period; age under 18.

Precautions:

Side effects

From the side of the cardiovascular system: often — palpitations, tachycardia, angina pectoris, arrhythmia, ventricular premature beats, orthostatic hypotension.

From the respiratory system: often — rhinitis, pharyngitis.

From the digestive system: very often diarrhea, stool disorders; often — nausea, vomiting, dyspepsia, flatulence, abdominal pain; infrequently — gastritis.